Last reviewed · How we verify
docetaxel and cisplatin
Docetaxel and cisplatin is a chemotherapy combination that kills cancer cells by disrupting microtubule dynamics and causing DNA damage through platinum-induced crosslinks.
Docetaxel and cisplatin is a chemotherapy combination that kills cancer cells by disrupting microtubule dynamics and causing DNA damage through platinum-induced crosslinks. Used for Non-small cell lung cancer, Head and neck cancer, Gastric cancer.
At a glance
| Generic name | docetaxel and cisplatin |
|---|---|
| Also known as | chemothrrapy, Taxotere, Taxotere；Platinol, TP, Docetaxel (Sanofi-Aventis) |
| Sponsor | Sanofi |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | Microtubules (docetaxel); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Docetaxel is a taxane that stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. Cisplatin is a platinum-based alkylating agent that forms DNA adducts and crosslinks, causing DNA damage and cell death. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Head and neck cancer
- Gastric cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
- Fatigue
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) (PHASE2)
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- docetaxel and cisplatin CI brief — competitive landscape report
- docetaxel and cisplatin updates RSS · CI watch RSS
- Sanofi portfolio CI